Health Care [ 9/12 ] | Biotechnology [ 61/74 ]
NASDAQ | Common Stock
Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States.
The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).
Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms.
The company offers AVISE Lupus platform, a cornerstone of the SLE assessment that begins by quantifying the level of CB-CAPs biomarkers (EC4d and BC4d) in the patient's blood; and AVISE APS that aids in the diagnosis and management of APS.
In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE Anti-Histone, a test for autoantibodies to histone proteins; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP, a biomarker-driven RA prognostic test.
Further, the company offers AVISE SLE Monitor, a blood test that employs CB-CAPs technology; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine.
It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop T-Cell biomarkers.
The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019.
Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 17, 25 | -0.20 Increased by +35.48% | -0.24 Increased by +16.67% |
| Nov 12, 24 | -0.28 Increased by +11.16% | -0.29 Increased by +5.03% |
| Aug 5, 24 | -0.16 Increased by +42.86% | -0.34 Increased by +52.94% |
| May 13, 24 | -0.19 Increased by +56.82% | -0.36 Increased by +47.22% |
| Mar 18, 24 | -0.31 Increased by +62.65% | -0.43 Increased by +27.91% |
| Nov 13, 23 | -0.31 Increased by +34.04% | -0.47 Increased by +34.04% |
| Aug 7, 23 | -0.28 Increased by +64.10% | -0.49 Increased by +42.86% |
| May 15, 23 | -0.44 Increased by +26.67% | -0.56 Increased by +21.43% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 13.65 M Decreased by -0.80% | -3.76 M Increased by +32.51% | Decreased by -27.54% Increased by +31.97% |
| Sep 30, 24 | 12.51 M Decreased by -6.78% | -5.03 M Increased by +7.15% | Decreased by -40.20% Increased by +0.40% |
| Jun 30, 24 | 15.06 M Increased by +6.56% | -2.97 M Increased by +40.83% | Decreased by -19.69% Increased by +44.47% |
| Mar 31, 24 | 14.41 M Increased by +28.36% | -3.36 M Increased by +56.30% | Decreased by -23.31% Increased by +65.95% |
| Dec 31, 23 | 13.77 M Increased by +7.23% | -5.57 M Increased by +61.17% | Decreased by -40.49% Increased by +63.79% |
| Sep 30, 23 | 13.42 M Decreased by -8.90% | -5.42 M Decreased by -128.96% | Decreased by -40.36% Decreased by -151.32% |
| Jun 30, 23 | 14.14 M Increased by +57.74% | -5.01 M Increased by +63.96% | Decreased by -35.46% Increased by +77.15% |
| Mar 31, 23 | 11.23 M Increased by +8.04% | -7.69 M Increased by +29.24% | Decreased by -68.46% Increased by +34.51% |